Madrid (ots/PRNewswire) - - IDMC Recommends Adoption of 24hr Dosing in Pivotal Trial PharmaMar today announces that the independent data monitoring committee (IDMC) for the pivotal trial of YONDELIS(R) in Soft Tissue Sarcoma (STS) has reviewed data from a pre-planned interim analysis of the primary end-point, Time to Progression (TTP), which indicate that ...
Lyon, France (ots/PRNewswire) - - Data Show That the Vaccine is Safe, Demonstrates Immunogenicity and Provides Future Direction for Development Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that preliminary results of clinical trials fielded in France of an adjuvanted ...
Alderley Park, England (ots/PRNewswire) - AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA(TM)) for the treatment of patients with medullary thyroid cancer in the European Union (EU). ...
Madrid (ots/PRNewswire) - PharmaMar today announces the results of the Aplidin(R) Phase II trial which were presented at the American Society of Hematology 47th Annual Meeting in Atlanta, Georgia, USA, on Sunday 11 December. Aplidin reached its objective of overall response rate established in the first stage of ...
Macclesfield, England (ots/PRNewswire) - - Replacing tamoxifen With Arimidex (TM) (anastrozole) Shown to Reduce Patient's Risk of Death by Nearly a Third Breakthrough new data presented today show breast cancer treatment 'Arimidex' (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) announced today nine month interim safety and efficacy data obtained from its 24 week Phase III psoriasis trial and 12 week extension for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an ...
Macclesfield, England (ots/PRNewswire) - 'New Data Outcomes in Early Breast Cancer: Improving the Odds for Survival' News that could change the landscape for hormonal treatments in postmenopausal women Room: 0001B, River Level, Henry B. Gonzalez Convention Center, ...
Cephalon, Inc.; Zeneus Holdings Limited
Frazer, Pennsylvania. and Oxford, England (ots/PRNewswire) - - Transaction Opens European Oncology Market for Cephalon; Creates Additional Direct Presence in Europe's Five Major Markets Cephalon, Inc. (Nasdaq: CEPH) and Zeneus Holdings Limited announced today that the companies have signed a definitive purchase agreement under which Cephalon, Inc. will acquire all of the outstanding share capital of Zeneus ...
Research Triangle Park, North Carolina (ots/PRNewswire) - - Now has clinical development offices in eight Asia countries Quintiles Transnational Corp. today announced the extension of its Asia operations with the opening of an office in Hanoi, Vietnam. "Vietnam is an increasingly important market in the region, with its population of 80 million, a strong educational system and a robust healthcare industry," ...
Zurich (ots) - Baxter Healthcare S.A. announced today that Baxter"s ready-to-use liquid 10% Intravenous Immunoglobulin (IVIG), has received unanimous positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). Once licensed, ...
Alderley Park, England, November 23 (ots/PRNewswire) - - First patient enrolled into double-blind, randomised, placebo-controlled study to investigate overall survival in a broad NSCLC population AstraZeneca (NYSE: AZN) announced today the start of recruitment into a pivotal Phase II/III study of the ...
Boca Raton, Florida, November 22 (ots/PRNewswire) - PharmaMar announces the presentation of data from two research projects at the 11th Annual CTOS (Connective Tissue Oncology Society) Meeting, which took place in Florida, USA, from November 19-21, 2005. The first presentation highlighted data from a retrospective study conducted in tumour samples from patients of soft tissue sarcoma treated with Yondelis(R) in ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - New hope for HIV/AIDS patients: APTIVUS(R) outperforms several commonly prescribed drugs in the protease inhibitor (PI) class DUBLIN, Ireland, November 21 /PRNewswire/ -- - Experts Emphasize Need for Effective Therapy in Response to Increased Prevalence of HIV/AIDS throughout Europe At the 10th European AIDS Clinical Society (EACS) conference, experts ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...
Dublin, Ireland, November 18 (ots/PRNewswire) - - Latest Advances in Health Psychology may Help Physicians Implement Improved HIV Care - News From 10th European AIDS Conference, Dublin, Ireland Initial results from the OpenMind study, the largest behavioural study to look at both patients' and ...
Lund, Switzerland, November 17 (ots/PRNewswire) - For Non-US Medical Journalists Only A new report on the importance of treating Chronic Obstructive Pulmonary Disease (COPD) exacerbations is launched today, on World COPD Day. Global dissemination of the report to family physicians/General Practitioners around the world is being supported and facilitated by ...
San Diego, California, November 17 (ots/PRNewswire) - - First Phase III Data Presented at the ACR Annual Meeting Roche today announced the results of the first Phase III study in rheumatoid arthritis (RA) conducted by Chugai in Japan which are being presented at the American College of Rheumatology (ACR) ...
Alderley Park, England, November 16 (ots/PRNewswire) - - New Data Add Momentum to AstraZeneca's Novel Oncology Drug, ZD6474 (ZACTIMA[TM]), Which has Already Shown Promising Data in Non-Small Cell Lung Cancer (NSCLC) Preliminary results from a Phase II study showing promising clinical data with ZD6474 ...
London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS(R) (pioglitazone) significantly reduced the occurrence of fatal ...
Edmonton, Canada, November 16 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA), a biopharmaceutical company focused on the discovery and development of novel immunosuppressive therapeutics, announced today that effective immediately, Joseph Koziak, who served as Executive Vice President is no longer an officer of the company. About Isotechnika Isotechnika Inc. is an international biopharmaceutical ...
Paris, November 16 (ots/PRNewswire) - - Emea Approves New Treatment for Chronic Stable Angina Procoralan (ivabradine, Servier), the first selective and specific If inhibitor, has received marketing authorization in 27 European countries from the European Medicines Evaluation Agency (EMEA) for the ...
Macclesfield, England, November 15 (ots/PRNewswire) - - For Health Professional Press Only - For International Journalists Only - Not for US Media - Retrospective ISEL Study Analysis Identifies Potential Indicator of Response to Treatment With gefitinib in Advanced NSCLC patients Data presented ...
Dallas, Texas, November 14 (ots/PRNewswire) - - FIELD Confirms Fenofibrate Produces Macrovascular and Microvascular Benefits in Diabetic Patients Without Previous Cardiovascular Disease Although Primary Endpoint is not met Results of the largest intervention study ever conducted for the prevention of ...
Dallas, Texas, November 14 (ots/PRNewswire) - - CAFÉ Study Shows Central Aortic Pulse Pressure Important Determinant of Cardiovascular Outcomes A new sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)(1), presented during a late breaking clinical trial session of the American Heart ...
Edmonton, Canada, November 7 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A summary of the results is as follows: - All primary and secondary efficacy endpoints were achieved at 24 weeks - Efficacy endpoints were ...
International Bureau for Epilepsy (IBE) & UCB
Sydney, November 7 (ots/PRNewswire) - - With Photos The first live performance of Brain Storm, a theatre production focused on epilepsy was staged today at the 2005 World Congress of Neurology in Sydney, Australia. Brain Storm dramatizes the devastating effect that uncontrolled seizures can have on the ...
Edmonton, Canada, November 4 (ots/PRNewswire) - - ATTN: Business/Assignment Editors: EDMONTON, Canada, November 4 /PRNewswire/ -- Isotechnika Inc. will announce the unaudited 24 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m. EST/5:00a.m. MST. Management will ...
Paris, November 2 (ots/PRNewswire) - The European School of Oncology (ESO) presented this year's joint winners of the ACE (Awarding Cancer Enlightenment) Reporter Award 2005 -- Viktoria Kun, Health Correspondent on the Hungarian national daily newspaper Nepszabadsag, and Ioanna Soufleri, Science Editor on the Greek national daily newspaper To Vima -- with euro 5,000 each at an award ceremony held today at the European ...
Basel, Switzerland (ots/PRNewswire) - The news that the innovative new cancer drug Tarceva(R) (erlotinib) is now becoming available across the EU will provide a glimmer of hope to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer. Not only has Tarceva demonstrated a striking survival benefit (42.5 per ...
Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be ...